PHARMACEUTICAL PRODUCTS OF RECOMBINANT DNA TECHNOLOGY: AN OVERVIEW
ABOUT AUTHOR:
Muhammad Mujahed
M.Sc Biotechnology
Swami Ramanand Teerth Marathwada University, Vishnupuri , Nanded.
mujubiotech2011@rediffmail.com
INTRODUCTION:
A few decades ago, it was realized that certain proteins could be used as pharmaceutical agents for the treatment of human diseases. e.g. insulin for diabetes mellitus, interferon for viral diseases. However the availability of such therapeutic/ pharmaceutical products was limited due to costly and cumbersome procedures involved in their isolation. Further, their use in humans was associated with several complications. For instance, administration of pig insulin to diabetic patients results in the development of antibodies.
The advent of recombinant DNA technology heralded a new chapter for the production of a wide range of therapeutic agents in sufficient quantities for human use. The commercial exploitation of recombinant DNA (rDNA) technology began in late 1970s by biotechnological companies to produce proteins.There are around 400 different proteins being produced by rDNAtechnologyand as of now around 30 have been approved for human use.